Literature DB >> 7711412

Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

H Albrecht1, H J Stellbrink, G Gross, B Berg, U Helmchen, H Mensing.   

Abstract

Visceral leishmaniasis (kala-azar) affecting HIV-infected patient is being reported in increasing frequency. A 40-year-old German bisexual patient with full-blown AIDS is described who presented with Kaposi's sarcoma, epigastric pain, diarrhea, and weight loss but without fever. Leishmania amastigotes were initially found in biopsies from stomach, duodenum, and a cutaneous Kaposi's sarcoma lesion but were later also recovered from bone marrow and lymph node. The patient received three courses of a combination of pentavalent antimony and interferon-gamma. In addition to the common side effects such as fever, thrombocytopenia, and elevated amylase and lipase, a vivid progression of the Kaposi's sarcoma was noted. Tumor progression was temporally closely associated with treatment with interferon-gamma. Because this phenomenon has also been observed in other patients, we advise caution when using interferon-gamma in patients with Kaposi's sarcoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711412     DOI: 10.1007/bf00577752

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  40 in total

1.  Gastric localization of systemic leishmaniasis in a patient with AIDS.

Authors:  L Delsedime; F Coppola; G Mazzucco
Journal:  Histopathology       Date:  1991-07       Impact factor: 5.087

2.  Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.

Authors:  R Badaro; E Falcoff; F S Badaro; E M Carvalho; D Pedral-Sampaio; A Barral; J S Carvalho; M Barral-Netto; M Brandely; L Silva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

3.  [Leishmaniasis of the upper gastrointestinal tract in an HIV positive patient].

Authors:  P Betz; C Elsing; J Purrmann; H Frenzel
Journal:  Pathologe       Date:  1990-03       Impact factor: 1.011

4.  [Asymptomatic visceral leishmaniasis in a patient with acquired immunodeficiency syndrome].

Authors:  G Sirera; F Millá; M J Condom; B Clotet
Journal:  Med Clin (Barc)       Date:  1990-02-10       Impact factor: 1.725

5.  Use of IFN-gamma in patients with AIDS.

Authors:  W Heagy; J Groopman; J Schindler; R Finberg
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

6.  Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain.

Authors:  C Montalban; R Martinez-Fernandez; J L Calleja; J D Garcia-Diaz; R Rubio; F Dronda; S Moreno; M Yebra; C Barros; J Cobo
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

7.  [Visceral leishmaniasis (kala-azar) in acquired immunodeficiency syndrome (AIDS)].

Authors:  G Just; R Simader; E B Helm; W Stille; S Falk; H J Stutte; K Hübner
Journal:  Dtsch Med Wochenschr       Date:  1988-12-09       Impact factor: 0.628

8.  A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).

Authors:  H C Lane; R T Davey; S A Sherwin; H Masur; A H Rook; J F Manischewitz; G V Quinnan; P D Smith; M E Easter; A S Fauci
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

9.  Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection.

Authors:  E M Carvalho; R S Teixeira; W D Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

10.  Visceral leishmaniasis (kala azar) in a patient with AIDS.

Authors:  D Smith; B Gazzard; R P Lindley; A Darwish; C Reed; A D Bryceson; D A Evans
Journal:  AIDS       Date:  1989-01       Impact factor: 4.177

View more
  5 in total

Review 1.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

2.  In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.

Authors:  A Fournet; M E Ferreira; A Rojas De Arias; S Torres De Ortiz; S Fuentes; H Nakayama; A Schinini; R Hocquemiller
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 3.  Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  Giovanni Barillari; Barbara Ensoli
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

Review 4.  Leishmaniasis-HIV coinfection: current challenges.

Authors:  José Angelo Lauletta Lindoso; Mirella Alves Cunha; Igor Thiago Queiroz; Carlos Henrique Valente Moreira
Journal:  HIV AIDS (Auckl)       Date:  2016-10-07

Review 5.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.